Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells

The purpose of this study is to understand how cells of the immune system use the common sugar glucose to fuel energy production and as a building block within the cell. Investigators will intravenously infuse a non-radioactive glucose tracer into participants over a few hours and collect immune cells from the blood to track uptake and usage of this glucose within these immune cells.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Glucose Immune System and Related Disorders Isotope Labeling Metabolism

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Vanderbilt University Medical Center

Nashville, Tennessee, 37212, United States

Location status: Recruiting

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adults aged 18 or older

Exclusion criteria

Pregnant
Prisoner or in police custody
Uncontrolled hyperglycemia/diabetes
Current participation in another study where the total volume of blood drawn, when added to this study blood draw volume, exceeds 500cc in an 8 week period
Any medical issue or pharmacologic exposure which, in the opinion of the study investigator, that might interfere with the study objectives
Any reason which, in the opinion of the study investigator, adds additional risk to the participant

Treatment and study plan

13C6-Glucose

Drug

Compounded as 5% 13C6-Glucose in sterile water given IV over 2-4 hours as a split bolus and infusion

Primary outcomes

13C6-glucose uptake in immune cells

Time frame: Up to 4 hours

Detection of 13C6-glucose-derived metabolites in neutrophils, monocytes, CD4 T cells, and CD8 T cells using gas and liquid chromatography-mass spectrometry (GC-MS and LC-MS) following magnetic enrichment of these immune cell subsets.

Study contacts

Contact information is provided by the study sponsor or research team.

Matthew T Stier, M.D., Ph.D.

CONTACT

[email protected]

615-875-4978

Sponsors and collaborators

Lead sponsor

Vanderbilt University Medical Center

Other

Registry information

Acronym: TORCH

Important dates

Study start: 2025
Primary completion: 2027
Study completion: 2027
First posted: Apr 16, 2025
Registry last updated: Nov 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting